Literature DB >> 19337169

Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.

Nicos Skordis1, Yiannis S Ioannou, Andreas Kyriakou, Savvas C Savva, Elisavet Efstathiou, Irene Savvides, Soteroulla Christou.   

Abstract

BACKGROUND: Bisphosphonates are potent inhibitors of osteoclastic bone resorption and have been recently used in thalassaemia major (TM) osteoporosis with encouraging results.
OBJECTIVE: The aim of the study is to investigate the effect of two Bisphosphonate drugs, Alendronate and Pamidronate on bone mass in patients of both genders with TM, treated in our Center. SUBJECTS AND METHODS: 53 (22 males, 31 females) Thalassaemic patients of Greek Cypriot origin were randomly divided into two groups. 29 patients in group A with a mean age of 33, 32 years were treated with alendronate and 24 patients in group B with a mean age of 34, 36 years received pamidronate for a period of 2 years. The effectiveness of both drugs was estimated based on the change of Bone mineral density (BMD) values of lumbar spine and femoral neck. Bone mineral density (BMD) of lumbar spine and femoral neck was measured by dual-energy X-ray absiorptiometry. All patients were on the standard treatment protocol of Thalassaemia. Statistical analysis was performed with the SPSS program.
RESULTS: After completion of treatment with pamidronate the mean lumbar spine BMD has improved from -2.813 to -2.174 (p<0.001) and the mean hip BMD from -2.138 to -2.078 (p=0.018). The change of spine BMD in patients who received alendronate was from -2.720 to -2.602 (p=0.059) and the changes in BMD at the femoral neck from -2.035 to -2.007 (p=0.829).
CONCLUSIONS: This study demonstrates the efficacy of two bisphosphonate drugs in improving BMD values in patients with TM and osteoporosis. Since the origin of bone disease in TM is multifactorial and some of the underlying pathogenic mechanisms are still unclear, further research in this field is needed, which will allow the design of optimal therapeutic measures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19337169

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  9 in total

Review 1.  Premenopausal Osteoporosis.

Authors:  Adi Cohen
Journal:  Endocrinol Metab Clin North Am       Date:  2016-11-24       Impact factor: 4.741

2.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

Review 3.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

4.  Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Authors:  Mohamed A Yassin; Ashraf T Soliman; Vincenzo De Sanctis; Mohamed Osman Abdelrahman; Elsaid M Aziz Bedair; Manal AbdelGawad
Journal:  Indian J Endocrinol Metab       Date:  2014-07

5.  Characterization of thalassemia major and diabetes mellitus patients at a reference center in Brazil.

Authors:  Gabriela Marsola Olivatto; Carla Regina de Souza Teixeira; Marcela Ganzella Sisdelli; Maria Lúcia Zanetti; Renata Cristina de Campos Pereira Silveira; Claudio Vinicius Gonçalves
Journal:  Hematol Transfus Cell Ther       Date:  2018-12-31

Review 6.  A contemporary therapeutic approach to bone disease in beta-thalassemia - a review.

Authors:  Dimitrios Stefanopoulos; Nikolaos A Papaioannou; Athanassios G Papavassiliou; George Mastorakos; Andromachi Vryonidou; Aikaterini Michou; Ismene A Dontas; George Lyritis; Eva Kassi; Symeon Tournis
Journal:  J Frailty Sarcopenia Falls       Date:  2018-03-01

7.  Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis.

Authors:  Mohamed A Yassin; Mohamed O Abdel Rahman; Anas A Hamad; Abdul Razzakh Poil; Mohamed T Abdelrazek; Radwa M Hussein; Nancy A Kassem; Afraa M Fadul; Sarah A Elkourashy; Abdulqadir J Nashwan
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

8.  Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Nicos Skordis; Christos Kattamis; Michael Angastiniotis; Mehran Karimi; Mohd Abdel Daem Mohd Yassin; Ahmed El Awwa; Iva Stoeva; Giuseppe Raiola; Maria Concetta Galati; Elsaid M Bedair; Bernadette Fiscina; Mohamed El Kholy
Journal:  Indian J Endocrinol Metab       Date:  2013-01

Review 9.  Assessment and clinical management of bone disease in adults with eating disorders: a review.

Authors:  Anne Drabkin; Micol S Rothman; Elizabeth Wassenaar; Margherita Mascolo; Philip S Mehler
Journal:  J Eat Disord       Date:  2017-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.